English

vTv Therapeutics Inc.

EDGAR

VTVT Quarterly report (10-Q) · filed 2026-08-06

Annual consolidated revenue for 2025: about USD 0, using the latest reported figures. The previous period, 2024, was about USD 1.017M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 0 USD Source

Operating cash flow

-11.4 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -2289000 USD Source
Operating Cash Flow: 9154000 USD Source

Cash and cash equivalents: 86.6 million USD 2026-06-30 Source
Exact value

86600000 USD
Long-term debt including current maturities: 5.04 million USD 2019-12-31 Source
Exact value

5041000 USD
Shares outstanding: 0 shares 2015-09-30 Source
Exact value

0 shares

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

36.8 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 0 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 0 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 0 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 36839000 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 0 USD · 2026-04-01 – 2026-06-30 Source

Net income

-4.76 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -8698000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -26974000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -19836000 USD · 2025-01-01 – 2025-09-30 Source
Net income: 24134000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -13054000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-16.8 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -16004000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -10782000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -25255000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -16004000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: 9154000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -2289000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: 9154000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-06.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2025-12-31
Operating income: 11 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 10 of 11 periods available· newest 2024-12-31
Total assets: 11 of 11 periods available· newest 2025-12-31
Total liabilities: 11 of 11 periods available· newest 2025-12-31
Current assets: 11 of 11 periods available· newest 2025-12-31
Current liabilities: 11 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2025-12-31
Long-term debt including current maturities: 3 of 11 periods available· newest 2019-12-31
shares outstanding: No compatible figures in this window

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-100%

Prior period

USD 1.02 million

2024-01-01 – 2024-12-31
Current period

USD 0

2025-01-01 – 2025-12-31

Exact inputs and evidence

0 − 1017000 = -1017000 USD

1017000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
0 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · vTv Therapeutics Inc. · 2025-12-31 vTv Therapeutics Inc. (edgar:1641489) Year-over-year change in Revenue: -1017000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 0 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000164148926000010/vtvt-20251231.htm#1340352 Filing: 000164148926000010 Input fundies:Revenue: 1017000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000164148926000010/vtvt-20251231.htm#1055419 Filing: 000164148926000010
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 8.51 million

Prior period

−USD 18.46 million

2024-01-01 – 2024-12-31
Current period

−USD 26.97 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-26974000 − -18462000 = -8512000 USD

-18462000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-26974000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · vTv Therapeutics Inc. · 2025-12-31 vTv Therapeutics Inc. (edgar:1641489) Year-over-year change in Net income: -8512000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -26974000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000164148926000010/vtvt-20251231.htm#1622935 Filing: 000164148926000010 Input fundies:NetIncome: -18462000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000164148926000010/vtvt-20251231.htm#1623558 Filing: 000164148926000010
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 52,000

Prior period

−USD 25.31 million

2024-01-01 – 2024-12-31
Current period

−USD 25.26 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-25255000 − -25307000 = 52000 USD

-25307000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-25255000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · vTv Therapeutics Inc. · 2025-12-31 vTv Therapeutics Inc. (edgar:1641489) Year-over-year change in Operating cash flow: 52000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -25255000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000164148926000010/vtvt-20251231.htm#1277461 Filing: 000164148926000010 Input fundies:OperatingCashFlow: -25307000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000164148926000010/vtvt-20251231.htm#1278113 Filing: 000164148926000010
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 0
Operating costs Derived USD 32.81 million
Operating income −USD 32.81 million
Tax, interest and other Derived −USD 5.83 million
Net income −USD 26.97 million

Cash

Operating cash flow −USD 25.26 million
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Operating loss: operating costs were 8,778% of revenue.
2017 Operating loss: operating costs were 17,516% of revenue.
2018 Operating loss: operating costs were 259% of revenue.
2019 Operating loss: operating costs were 856% of revenue.
2020 Operating loss: operating costs were 285% of revenue.
2021 Operating loss: operating costs were 641% of revenue.
2022 Operating loss: operating costs were 1,217% of revenue.
2023 Not shown: operating income or net income is not reported.
2024 Operating loss: operating costs were 2,478% of revenue.
2025 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	634000	55654000 Derived	-55020000	-38668000 Derived	-16352000	-48296000 Derived	Source 2016-01-01 – 2016-12-31: 634000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -55020000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -16352000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -48209000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 87000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	291000	50973000 Derived	-50682000	-34538000 Derived	-16144000	-44617000 Derived	Source 2017-01-01 – 2017-12-31: 291000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -50682000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -16144000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -44560000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 57000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	12434000	32258000 Derived	-19824000	-11913000 Derived	-7911000	-26861000 Derived	Source 2018-01-01 – 2018-12-31: 12434000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -19824000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -7911000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -26856000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 5000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	2764000	23656000 Derived	-20892000	-7848000 Derived	-13044000	-23088000 Derived	Source 2019-01-01 – 2019-12-31: 2764000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -20892000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -13044000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -23018000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 70000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	6414000	18266000 Derived	-11852000	-3353000 Derived	-8499000	-18000000 Derived	Source 2020-01-01 – 2020-12-31: 6414000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -11852000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -8499000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -18000000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 0 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	4005000	25667000 Derived	-21662000	-8675000 Derived	-12987000	-19308000 Derived	Source 2021-01-01 – 2021-12-31: 4005000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -21662000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -12987000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -19308000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 0 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	2018000	24558000 Derived	-22540000	-3376000 Derived	-19164000	-16043000 Derived	Source 2022-01-01 – 2022-12-31: 2018000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -22540000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -19164000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -16022000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 21000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	0	25502000 Derived	-25502000	-5252000 Derived	-20250000	-19081000 Derived	Source 2023-01-01 – 2023-12-31: 0 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -25502000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -20250000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -19081000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 0 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	1017000	25197000 Derived	-24180000	-5718000 Derived	-18462000	-25307000 Derived	Source 2024-01-01 – 2024-12-31: 1017000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -24180000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -18462000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -25307000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 0 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	0	32808000 Derived	-32808000	-5834000 Derived	-26974000	Unavailable	Source 2025-01-01 – 2025-12-31: 0 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -32808000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -26974000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -25255000 USD Inspect Operating Cash Flow Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Revenue	634000	Revenue: 634000 Open source
20172017-12-31	Revenue	291000	Revenue: 291000 Open source
20182018-12-31	Revenue	12434000	Revenue: 12434000 Open source
20192019-12-31	Revenue	2764000	Revenue: 2764000 Open source
20202020-12-31	Revenue	6414000	Revenue: 6414000 Open source
20212021-12-31	Revenue	4005000	Revenue: 4005000 Open source
20222022-12-31	Revenue	2018000	Revenue: 2018000 Open source
20232023-12-31	Revenue	0	Revenue: 0 Open source
20242024-12-31	Revenue	1017000	Revenue: 1017000 Open source
20252025-12-31	Revenue	0	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-100% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	22.2%	Revenue: 634000 Open source Revenue: 519000 Open source
20172017-12-31	Year over year	-54.1%	Revenue: 291000 Open source Revenue: 634000 Open source
20182018-12-31	Year over year	4,172.9%	Revenue: 12434000 Open source Revenue: 291000 Open source
20192019-12-31	Year over year	-77.8%	Revenue: 2764000 Open source Revenue: 12434000 Open source
20202020-12-31	Year over year	132.1%	Revenue: 6414000 Open source Revenue: 2764000 Open source
20212021-12-31	Year over year	-37.6%	Revenue: 4005000 Open source Revenue: 6414000 Open source
20222022-12-31	Year over year	-49.6%	Revenue: 2018000 Open source Revenue: 4005000 Open source
20232023-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 2018000 Open source
20242024-12-31	Year over year	No prior comparable period	Revenue: 1017000 Open source Revenue: 0 Open source
20252025-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 1017000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -2,377.6% 2024

Net margin -1,815.3% 2024

Free cash flow margin -2,488.4% 2024

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	-8,678.2%	Operating Income: -55020000 Open source Revenue: 634000 Open source
20172017-12-31	Operating margin	-17,416.5%	Operating Income: -50682000 Open source Revenue: 291000 Open source
20182018-12-31	Operating margin	-159.4%	Operating Income: -19824000 Open source Revenue: 12434000 Open source
20192019-12-31	Operating margin	-755.9%	Operating Income: -20892000 Open source Revenue: 2764000 Open source
20202020-12-31	Operating margin	-184.8%	Operating Income: -11852000 Open source Revenue: 6414000 Open source
20212021-12-31	Operating margin	-540.9%	Operating Income: -21662000 Open source Revenue: 4005000 Open source
20222022-12-31	Operating margin	-1,116.9%	Operating Income: -22540000 Open source Revenue: 2018000 Open source
20232023-12-31	Operating margin	Not reported	Operating Income: -25502000 Open source Revenue: 0 Open source
20242024-12-31	Operating margin	-2,377.6%	Operating Income: -24180000 Open source Revenue: 1017000 Open source
20252025-12-31	Operating margin	Not reported	Operating Income: -32808000 Open source Revenue: 0 Open source
20162016-12-31	Net margin	-2,579.2%	Net Income: -16352000 Open source Revenue: 634000 Open source
20172017-12-31	Net margin	-5,547.8%	Net Income: -16144000 Open source Revenue: 291000 Open source
20182018-12-31	Net margin	-63.6%	Net Income: -7911000 Open source Revenue: 12434000 Open source
20192019-12-31	Net margin	-471.9%	Net Income: -13044000 Open source Revenue: 2764000 Open source
20202020-12-31	Net margin	-132.5%	Net Income: -8499000 Open source Revenue: 6414000 Open source
20212021-12-31	Net margin	-324.3%	Net Income: -12987000 Open source Revenue: 4005000 Open source
20222022-12-31	Net margin	-949.7%	Net Income: -19164000 Open source Revenue: 2018000 Open source
20232023-12-31	Net margin	Not reported	Net Income: -20250000 Open source Revenue: 0 Open source
20242024-12-31	Net margin	-1,815.3%	Net Income: -18462000 Open source Revenue: 1017000 Open source
20252025-12-31	Net margin	Not reported	Net Income: -26974000 Open source Revenue: 0 Open source
20162016-12-31	Free cash flow margin	-7,617.7%	Revenue: 634000 Open source Operating Cash Flow: -48209000 Open source Capital Expenditure: 87000 Open source
20172017-12-31	Free cash flow margin	-15,332.3%	Revenue: 291000 Open source Operating Cash Flow: -44560000 Open source Capital Expenditure: 57000 Open source
20182018-12-31	Free cash flow margin	-216%	Revenue: 12434000 Open source Operating Cash Flow: -26856000 Open source Capital Expenditure: 5000 Open source
20192019-12-31	Free cash flow margin	-835.3%	Revenue: 2764000 Open source Operating Cash Flow: -23018000 Open source Capital Expenditure: 70000 Open source
20202020-12-31	Free cash flow margin	-280.6%	Revenue: 6414000 Open source Operating Cash Flow: -18000000 Open source Capital Expenditure: 0 Open source
20212021-12-31	Free cash flow margin	-482.1%	Revenue: 4005000 Open source Operating Cash Flow: -19308000 Open source Capital Expenditure: 0 Open source
20222022-12-31	Free cash flow margin	-795%	Revenue: 2018000 Open source Operating Cash Flow: -16022000 Open source Capital Expenditure: 21000 Open source
20232023-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -19081000 Open source Capital Expenditure: 0 Open source
20242024-12-31	Free cash flow margin	-2,488.4%	Revenue: 1017000 Open source Operating Cash Flow: -25307000 Open source Capital Expenditure: 0 Open source
20252025-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -25255000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -25.3M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	-48209000	Operating Cash Flow: -48209000 Open source
20172017-12-31	Operating cash flow	-44560000	Operating Cash Flow: -44560000 Open source
20182018-12-31	Operating cash flow	-26856000	Operating Cash Flow: -26856000 Open source
20192019-12-31	Operating cash flow	-23018000	Operating Cash Flow: -23018000 Open source
20202020-12-31	Operating cash flow	-18000000	Operating Cash Flow: -18000000 Open source
20212021-12-31	Operating cash flow	-19308000	Operating Cash Flow: -19308000 Open source
20222022-12-31	Operating cash flow	-16022000	Operating Cash Flow: -16022000 Open source
20232023-12-31	Operating cash flow	-19081000	Operating Cash Flow: -19081000 Open source
20242024-12-31	Operating cash flow	-25307000	Operating Cash Flow: -25307000 Open source
20252025-12-31	Operating cash flow	-25255000	Operating Cash Flow: -25255000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -25.3M 2024

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Free cash flow	-48296000	Operating Cash Flow: -48209000 Open source Capital Expenditure: 87000 Open source
20172017-12-31	Free cash flow	-44617000	Operating Cash Flow: -44560000 Open source Capital Expenditure: 57000 Open source
20182018-12-31	Free cash flow	-26861000	Operating Cash Flow: -26856000 Open source Capital Expenditure: 5000 Open source
20192019-12-31	Free cash flow	-23088000	Operating Cash Flow: -23018000 Open source Capital Expenditure: 70000 Open source
20202020-12-31	Free cash flow	-18000000	Operating Cash Flow: -18000000 Open source Capital Expenditure: 0 Open source
20212021-12-31	Free cash flow	-19308000	Operating Cash Flow: -19308000 Open source Capital Expenditure: 0 Open source
20222022-12-31	Free cash flow	-16043000	Operating Cash Flow: -16022000 Open source Capital Expenditure: 21000 Open source
20232023-12-31	Free cash flow	-19081000	Operating Cash Flow: -19081000 Open source Capital Expenditure: 0 Open source
20242024-12-31	Free cash flow	-25307000	Operating Cash Flow: -25307000 Open source Capital Expenditure: 0 Open source
20252025-12-31	Free cash flow	Unavailable	Operating Cash Flow: -25255000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

28.3% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Liabilities / assets	42.1%	Total Liabilities: 22925000 Open source Total Assets: 54495000 Open source
20172017-12-31	Liabilities / assets	170.2%	Total Liabilities: 47524000 Open source Total Assets: 27917000 Open source
20182018-12-31	Liabilities / assets	338%	Total Liabilities: 28930000 Open source Total Assets: 8559000 Open source
20192019-12-31	Liabilities / assets	195.4%	Total Liabilities: 18106000 Open source Total Assets: 9266000 Open source
20202020-12-31	Liabilities / assets	74.4%	Total Liabilities: 10996000 Open source Total Assets: 14789000 Open source
20212021-12-31	Liabilities / assets	40.2%	Total Liabilities: 10252000 Open source Total Assets: 25474000 Open source
20222022-12-31	Liabilities / assets	82.4%	Total Liabilities: 27399000 Open source Total Assets: 33238000 Open source
20232023-12-31	Liabilities / assets	268.4%	Total Liabilities: 29567000 Open source Total Assets: 11018000 Open source
20242024-12-31	Liabilities / assets	62.6%	Total Liabilities: 23965000 Open source Total Assets: 38266000 Open source
20252025-12-31	Liabilities / assets	28.3%	Total Liabilities: 25462000 Open source Total Assets: 89899000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

13.54× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Current assets / current liabilities	4.56×	Current Assets: 52117000 Open source Current Liabilities: 11434000 Open source
20172017-12-31	Current assets / current liabilities	0.76×	Current Assets: 20362000 Open source Current Liabilities: 26929000 Open source
20182018-12-31	Current assets / current liabilities	0.18×	Current Assets: 3473000 Open source Current Liabilities: 18837000 Open source
20192019-12-31	Current assets / current liabilities	0.21×	Current Assets: 2838000 Open source Current Liabilities: 13381000 Open source
20202020-12-31	Current assets / current liabilities	1.13×	Current Assets: 7215000 Open source Current Liabilities: 6390000 Open source
20212021-12-31	Current assets / current liabilities	1.84×	Current Assets: 15621000 Open source Current Liabilities: 8498000 Open source
20222022-12-31	Current assets / current liabilities	3.52×	Current Assets: 27094000 Open source Current Liabilities: 7708000 Open source
20232023-12-31	Current assets / current liabilities	1×	Current Assets: 10657000 Open source Current Liabilities: 10619000 Open source
20242024-12-31	Current assets / current liabilities	7.34×	Current Assets: 38113000 Open source Current Liabilities: 5196000 Open source
20252025-12-31	Current assets / current liabilities	13.54×	Current Assets: 89893000 Open source Current Liabilities: 6641000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 16.35 million Exact value Exact value: -16352000 USD 2016-01-01 – 2016-12-31: -16352000 USD Inspect Net Income Open source Share or cite Citation for Net Income · vTv Therapeutics Inc. · 2016-12-31 vTv Therapeutics Inc. (edgar:1641489) Net Income: -16352000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -16352000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000156459019004516/vtvt-20181231.xml#183964 Filing: 000156459019004516 The citation records this snapshot. The page link may show a newer release later.	−USD 48.21 million Exact value Exact value: -48209000 USD 2016-01-01 – 2016-12-31: -48209000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · vTv Therapeutics Inc. · 2016-12-31 vTv Therapeutics Inc. (edgar:1641489) Operating Cash Flow: -48209000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -48209000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000156459019004516/vtvt-20181231.xml#213387 Filing: 000156459019004516 The citation records this snapshot. The page link may show a newer release later.	USD 87,000 Exact value Exact value: 87000 USD 2016-01-01 – 2016-12-31: 87000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · vTv Therapeutics Inc. · 2016-12-31 vTv Therapeutics Inc. (edgar:1641489) Capital Expenditure: 87000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 87000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000156459019004516/vtvt-20181231.xml#214649 Filing: 000156459019004516 The citation records this snapshot. The page link may show a newer release later.	−USD 48.3 million Calculation and evidence -48209000 − 87000 USD Exact free cash flow: -48296000 USD 2016-01-01 – 2016-12-31: -48209000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 87000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · vTv Therapeutics Inc. · 2016-12-31 vTv Therapeutics Inc. (edgar:1641489) Free cash flow: -48296000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -48209000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000156459019004516/vtvt-20181231.xml#213387 Filing: 000156459019004516 Input fundies:CapitalExpenditure: 87000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000156459019004516/vtvt-20181231.xml#214649 Filing: 000156459019004516 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 16.14 million Exact value Exact value: -16144000 USD 2017-01-01 – 2017-12-31: -16144000 USD Inspect Net Income Open source Share or cite Citation for Net Income · vTv Therapeutics Inc. · 2017-12-31 vTv Therapeutics Inc. (edgar:1641489) Net Income: -16144000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -16144000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000156459020005627/vtvt-20191231.xml#216629 Filing: 000156459020005627 The citation records this snapshot. The page link may show a newer release later.	−USD 44.56 million Exact value Exact value: -44560000 USD 2017-01-01 – 2017-12-31: -44560000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · vTv Therapeutics Inc. · 2017-12-31 vTv Therapeutics Inc. (edgar:1641489) Operating Cash Flow: -44560000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -44560000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000156459020005627/vtvt-20191231.xml#246263 Filing: 000156459020005627 The citation records this snapshot. The page link may show a newer release later.	USD 57,000 Exact value Exact value: 57000 USD 2017-01-01 – 2017-12-31: 57000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · vTv Therapeutics Inc. · 2017-12-31 vTv Therapeutics Inc. (edgar:1641489) Capital Expenditure: 57000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 57000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000156459020005627/vtvt-20191231.xml#247527 Filing: 000156459020005627 The citation records this snapshot. The page link may show a newer release later.	−USD 44.62 million Calculation and evidence -44560000 − 57000 USD Exact free cash flow: -44617000 USD 2017-01-01 – 2017-12-31: -44560000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 57000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · vTv Therapeutics Inc. · 2017-12-31 vTv Therapeutics Inc. (edgar:1641489) Free cash flow: -44617000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -44560000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000156459020005627/vtvt-20191231.xml#246263 Filing: 000156459020005627 Input fundies:CapitalExpenditure: 57000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000156459020005627/vtvt-20191231.xml#247527 Filing: 000156459020005627 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 7.91 million Exact value Exact value: -7911000 USD 2018-01-01 – 2018-12-31: -7911000 USD Inspect Net Income Open source Share or cite Citation for Net Income · vTv Therapeutics Inc. · 2018-12-31 vTv Therapeutics Inc. (edgar:1641489) Net Income: -7911000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -7911000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000156459021008149/vtvt-20201231.xml#236118 Filing: 000156459021008149 The citation records this snapshot. The page link may show a newer release later.	−USD 26.86 million Exact value Exact value: -26856000 USD 2018-01-01 – 2018-12-31: -26856000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · vTv Therapeutics Inc. · 2018-12-31 vTv Therapeutics Inc. (edgar:1641489) Operating Cash Flow: -26856000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -26856000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000156459021008149/vtvt-20201231.xml#268343 Filing: 000156459021008149 The citation records this snapshot. The page link may show a newer release later.	USD 5,000 Exact value Exact value: 5000 USD 2018-01-01 – 2018-12-31: 5000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · vTv Therapeutics Inc. · 2018-12-31 vTv Therapeutics Inc. (edgar:1641489) Capital Expenditure: 5000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000156459021008149/vtvt-20201231.xml#269188 Filing: 000156459021008149 The citation records this snapshot. The page link may show a newer release later.	−USD 26.86 million Calculation and evidence -26856000 − 5000 USD Exact free cash flow: -26861000 USD 2018-01-01 – 2018-12-31: -26856000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 5000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · vTv Therapeutics Inc. · 2018-12-31 vTv Therapeutics Inc. (edgar:1641489) Free cash flow: -26861000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -26856000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000156459021008149/vtvt-20201231.xml#268343 Filing: 000156459021008149 Input fundies:CapitalExpenditure: 5000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000156459021008149/vtvt-20201231.xml#269188 Filing: 000156459021008149 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 13.04 million Exact value Exact value: -13044000 USD 2019-01-01 – 2019-12-31: -13044000 USD Inspect Net Income Open source Share or cite Citation for Net Income · vTv Therapeutics Inc. · 2019-12-31 vTv Therapeutics Inc. (edgar:1641489) Net Income: -13044000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -13044000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000156459022012258/vtvt-10k_20211231.htm#3056310 Filing: 000156459022012258 The citation records this snapshot. The page link may show a newer release later.	−USD 23.02 million Exact value Exact value: -23018000 USD 2019-01-01 – 2019-12-31: -23018000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · vTv Therapeutics Inc. · 2019-12-31 vTv Therapeutics Inc. (edgar:1641489) Operating Cash Flow: -23018000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -23018000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000156459022012258/vtvt-10k_20211231.htm#2203921 Filing: 000156459022012258 The citation records this snapshot. The page link may show a newer release later.	USD 70,000 Exact value Exact value: 70000 USD 2019-01-01 – 2019-12-31: 70000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · vTv Therapeutics Inc. · 2019-12-31 vTv Therapeutics Inc. (edgar:1641489) Capital Expenditure: 70000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 70000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000156459022012258/vtvt-10k_20211231.htm#2219939 Filing: 000156459022012258 The citation records this snapshot. The page link may show a newer release later.	−USD 23.09 million Calculation and evidence -23018000 − 70000 USD Exact free cash flow: -23088000 USD 2019-01-01 – 2019-12-31: -23018000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 70000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · vTv Therapeutics Inc. · 2019-12-31 vTv Therapeutics Inc. (edgar:1641489) Free cash flow: -23088000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -23018000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000156459022012258/vtvt-10k_20211231.htm#2203921 Filing: 000156459022012258 Input fundies:CapitalExpenditure: 70000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000156459022012258/vtvt-10k_20211231.htm#2219939 Filing: 000156459022012258 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 8.5 million Exact value Exact value: -8499000 USD 2020-01-01 – 2020-12-31: -8499000 USD Inspect Net Income Open source Share or cite Citation for Net Income · vTv Therapeutics Inc. · 2020-12-31 vTv Therapeutics Inc. (edgar:1641489) Net Income: -8499000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -8499000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000164148923000008/vtvt-20221231.htm#2081581 Filing: 000164148923000008 The citation records this snapshot. The page link may show a newer release later.	−USD 18 million Exact value Exact value: -18000000 USD 2020-01-01 – 2020-12-31: -18000000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · vTv Therapeutics Inc. · 2020-12-31 vTv Therapeutics Inc. (edgar:1641489) Operating Cash Flow: -18000000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -18000000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000164148923000008/vtvt-20221231.htm#1372083 Filing: 000164148923000008 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2020-01-01 – 2020-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · vTv Therapeutics Inc. · 2020-12-31 vTv Therapeutics Inc. (edgar:1641489) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000164148923000008/vtvt-20221231.htm#1376402 Filing: 000164148923000008 The citation records this snapshot. The page link may show a newer release later.	−USD 18 million Calculation and evidence -18000000 − 0 USD Exact free cash flow: -18000000 USD 2020-01-01 – 2020-12-31: -18000000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · vTv Therapeutics Inc. · 2020-12-31 vTv Therapeutics Inc. (edgar:1641489) Free cash flow: -18000000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -18000000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000164148923000008/vtvt-20221231.htm#1372083 Filing: 000164148923000008 Input fundies:CapitalExpenditure: 0 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000164148923000008/vtvt-20221231.htm#1376402 Filing: 000164148923000008 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 12.99 million Exact value Exact value: -12987000 USD 2021-01-01 – 2021-12-31: -12987000 USD Inspect Net Income Open source Share or cite Citation for Net Income · vTv Therapeutics Inc. · 2021-12-31 vTv Therapeutics Inc. (edgar:1641489) Net Income: -12987000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -12987000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000164148924000012/vtvt-20231231.htm#1719356 Filing: 000164148924000012 The citation records this snapshot. The page link may show a newer release later.	−USD 19.31 million Exact value Exact value: -19308000 USD 2021-01-01 – 2021-12-31: -19308000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · vTv Therapeutics Inc. · 2021-12-31 vTv Therapeutics Inc. (edgar:1641489) Operating Cash Flow: -19308000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -19308000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000164148924000012/vtvt-20231231.htm#1270689 Filing: 000164148924000012 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2021-01-01 – 2021-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · vTv Therapeutics Inc. · 2021-12-31 vTv Therapeutics Inc. (edgar:1641489) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000164148924000012/vtvt-20231231.htm#1275854 Filing: 000164148924000012 The citation records this snapshot. The page link may show a newer release later.	−USD 19.31 million Calculation and evidence -19308000 − 0 USD Exact free cash flow: -19308000 USD 2021-01-01 – 2021-12-31: -19308000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · vTv Therapeutics Inc. · 2021-12-31 vTv Therapeutics Inc. (edgar:1641489) Free cash flow: -19308000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -19308000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000164148924000012/vtvt-20231231.htm#1270689 Filing: 000164148924000012 Input fundies:CapitalExpenditure: 0 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000164148924000012/vtvt-20231231.htm#1275854 Filing: 000164148924000012 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 19.16 million Exact value Exact value: -19164000 USD 2022-01-01 – 2022-12-31: -19164000 USD Inspect Net Income Open source Share or cite Citation for Net Income · vTv Therapeutics Inc. · 2022-12-31 vTv Therapeutics Inc. (edgar:1641489) Net Income: -19164000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -19164000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000164148925000014/vtvt-20241231.htm#1760623 Filing: 000164148925000014 The citation records this snapshot. The page link may show a newer release later.	−USD 16.02 million Exact value Exact value: -16022000 USD 2022-01-01 – 2022-12-31: -16022000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · vTv Therapeutics Inc. · 2022-12-31 vTv Therapeutics Inc. (edgar:1641489) Operating Cash Flow: -16022000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -16022000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000164148925000014/vtvt-20241231.htm#1312830 Filing: 000164148925000014 The citation records this snapshot. The page link may show a newer release later.	USD 21,000 Exact value Exact value: 21000 USD 2022-01-01 – 2022-12-31: 21000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · vTv Therapeutics Inc. · 2022-12-31 vTv Therapeutics Inc. (edgar:1641489) Capital Expenditure: 21000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 21000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000164148925000014/vtvt-20241231.htm#1318029 Filing: 000164148925000014 The citation records this snapshot. The page link may show a newer release later.	−USD 16.04 million Calculation and evidence -16022000 − 21000 USD Exact free cash flow: -16043000 USD 2022-01-01 – 2022-12-31: -16022000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 21000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · vTv Therapeutics Inc. · 2022-12-31 vTv Therapeutics Inc. (edgar:1641489) Free cash flow: -16043000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -16022000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000164148925000014/vtvt-20241231.htm#1312830 Filing: 000164148925000014 Input fundies:CapitalExpenditure: 21000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000164148925000014/vtvt-20241231.htm#1318029 Filing: 000164148925000014 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 20.25 million Exact value Exact value: -20250000 USD 2023-01-01 – 2023-12-31: -20250000 USD Inspect Net Income Open source Share or cite Citation for Net Income · vTv Therapeutics Inc. · 2023-12-31 vTv Therapeutics Inc. (edgar:1641489) Net Income: -20250000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -20250000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000164148926000010/vtvt-20251231.htm#1624182 Filing: 000164148926000010 The citation records this snapshot. The page link may show a newer release later.	−USD 19.08 million Exact value Exact value: -19081000 USD 2023-01-01 – 2023-12-31: -19081000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · vTv Therapeutics Inc. · 2023-12-31 vTv Therapeutics Inc. (edgar:1641489) Operating Cash Flow: -19081000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -19081000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000164148926000010/vtvt-20251231.htm#1278766 Filing: 000164148926000010 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2023-01-01 – 2023-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · vTv Therapeutics Inc. · 2023-12-31 vTv Therapeutics Inc. (edgar:1641489) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000164148925000014/vtvt-20241231.htm#1317431 Filing: 000164148925000014 The citation records this snapshot. The page link may show a newer release later.	−USD 19.08 million Calculation and evidence -19081000 − 0 USD Exact free cash flow: -19081000 USD 2023-01-01 – 2023-12-31: -19081000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · vTv Therapeutics Inc. · 2023-12-31 vTv Therapeutics Inc. (edgar:1641489) Free cash flow: -19081000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -19081000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000164148926000010/vtvt-20251231.htm#1278766 Filing: 000164148926000010 Input fundies:CapitalExpenditure: 0 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000164148925000014/vtvt-20241231.htm#1317431 Filing: 000164148925000014 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 18.46 million Exact value Exact value: -18462000 USD 2024-01-01 – 2024-12-31: -18462000 USD Inspect Net Income Open source Share or cite Citation for Net Income · vTv Therapeutics Inc. · 2024-12-31 vTv Therapeutics Inc. (edgar:1641489) Net Income: -18462000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -18462000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000164148926000010/vtvt-20251231.htm#1623558 Filing: 000164148926000010 The citation records this snapshot. The page link may show a newer release later.	−USD 25.31 million Exact value Exact value: -25307000 USD 2024-01-01 – 2024-12-31: -25307000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · vTv Therapeutics Inc. · 2024-12-31 vTv Therapeutics Inc. (edgar:1641489) Operating Cash Flow: -25307000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -25307000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000164148926000010/vtvt-20251231.htm#1278113 Filing: 000164148926000010 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2024-01-01 – 2024-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · vTv Therapeutics Inc. · 2024-12-31 vTv Therapeutics Inc. (edgar:1641489) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000164148925000014/vtvt-20241231.htm#1316835 Filing: 000164148925000014 The citation records this snapshot. The page link may show a newer release later.	−USD 25.31 million Calculation and evidence -25307000 − 0 USD Exact free cash flow: -25307000 USD 2024-01-01 – 2024-12-31: -25307000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · vTv Therapeutics Inc. · 2024-12-31 vTv Therapeutics Inc. (edgar:1641489) Free cash flow: -25307000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -25307000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000164148926000010/vtvt-20251231.htm#1278113 Filing: 000164148926000010 Input fundies:CapitalExpenditure: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000164148925000014/vtvt-20241231.htm#1316835 Filing: 000164148925000014 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 26.97 million Exact value Exact value: -26974000 USD 2025-01-01 – 2025-12-31: -26974000 USD Inspect Net Income Open source Share or cite Citation for Net Income · vTv Therapeutics Inc. · 2025-12-31 vTv Therapeutics Inc. (edgar:1641489) Net Income: -26974000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -26974000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000164148926000010/vtvt-20251231.htm#1622935 Filing: 000164148926000010 The citation records this snapshot. The page link may show a newer release later.	−USD 25.26 million Exact value Exact value: -25255000 USD 2025-01-01 – 2025-12-31: -25255000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · vTv Therapeutics Inc. · 2025-12-31 vTv Therapeutics Inc. (edgar:1641489) Operating Cash Flow: -25255000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:00:40Z Snapshot: 7310e569154e247cd0c714edc835c714415b4051ec43bf85cf845fb5a1e6f057 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1641489/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -25255000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1641489/000164148926000010/vtvt-20251231.htm#1277461 Filing: 000164148926000010 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

57 filings · 2,661 latest values · 2,661 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001641489, 1641489, VTVT, edgar:1641489

Also known as vTv Therapeutics Inc.

vTv Therapeutics Inc.

Latest quarter

Revenue

Operating cash flow

Trailing twelve months

Revenue

Net income

Operating cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation